We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Electrical Impedance Tomography Developed to Identify Brain Hemorrhaging in Preterm Babies

By LabMedica International staff writers
Posted on 11 Oct 2012
A new US grant is helping researchers to develop a device that not only monitors preterm infants’ delicate brains, but also identifies intraventricular bleeding as soon as it begins. More...
The research should also give physicians a more detailed determination and timeline of how and when brain hemorrhages typically occur in babies.

Nearly one-third of premature infants develop bleeding in the brain after birth, a problem linked with serious long-term effects such as cerebral palsy, blindness, and seizures. But some of these severe complications could be prevented if physicians could identify and treat such brain hemorrhaging, also called intraventricular bleeding, when it begins.

To accomplish this, University of Florida (Gainesville, USA) researchers from the colleges of medicine and engineering have received a two-year, USD 694,000 grant from the US National Institute of Neurological Disorders and Stroke (Bethesda, MD, USA) in collaboration with EGI, Inc. (Eugene, OR, USA) to develop the technology.

“When we look at preterm babies with intraventricular hemorrhages, we detect them after the fact, so we really don’t know what is happening in the brain at the time of the hemorrhage,” said Dr. Michael Weiss, a neonatologist and an associate professor of pediatrics in the College of Medicine who has teamed with biomedical engineer Dr. Rosalind Sadleir, from the College of Engineering, on the project. “If we can identify the exact moment when a bleed occurs, we may be able to develop therapies that can help prevent bad outcomes from happening.”

The researchers will utilize a technique known as electrical impedance tomography (EIT). Using this method, they will be able to view three-dimensional (3D) reconstructions of hemorrhaging inside the brain at any given time, noted Dr. Sadleir, who specializes in the use of EIT to detect bleeding inside the body.

To gather data within the brain, small electrodes are placed on the head. For babies, the researchers plan to use eight electrodes, which they will place on an easy-to-apply bandage. “We collect 182 measurements in the head, and from that we make our picture,” Dr. Sadleir said.

While infants are hooked up to the electrodes, their brains will be constantly scanned for signs of hemorrhaging. If bleeding reaches a dangerous level, an alert will sound, similar to other devices used to monitor premature babies in the neonatal intensive care unit.

Brain bleeding is typically detected through regular ultrasound scanning performed about seven to 14 days after a premature baby is born, according to the National Institutes of Health. Most of the time there are no other symptoms that alert doctors to the bleeding. “If we detect bleeding right when it starts, we have a much better chance of mitigating ill effects and also preventing other secondary conditions that happen after a bleed,” Dr. Sadleir said.

EIT is used commercially in lung monitoring, specifically to measure lung activity when patients are placed on ventilators to assist their breathing. Unlike magnetic resonance imaging (MRI) or computed tomography (CT) scans, the images generated through EIT at times look a little blurry because electrical currents do not travel in straight lines, according to Dr. Sadleir. However, the health care team will not study the images in the neonatal intensive care unit (NICU); instead, the readings will translate to a number. This number will be compared with an acceptable baseline. When bleeding is found, the clinicians can then review the image and perform an ultrasound scan to more effectively target the problem.

“We do a lot of general monitoring in the NICU, but we don’t look at a lot of the end organs, such as the brain,” Dr. Weiss said. “We are starting to find out more and more about babies by using brain-specific monitoring. This knowledge may improve outcomes in preterm babies.”

Related Links:

University of Florida
US National Institute of Neurological Disorders and Stroke
EGI



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Portable POCT Blood Gas Analyzer
BD100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.